191 related articles for article (PubMed ID: 28028124)
1. Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
J Pharmacol Exp Ther; 2017 Mar; 360(3):445-456. PubMed ID: 28028124
[TBL] [Abstract][Full Text] [Related]
2. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
AAPS J; 2019 Jan; 21(2):23. PubMed ID: 30706160
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
Zhang J; Jiang H; Mao Z; Wang X; Fan X; Liu Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):335-40. PubMed ID: 25030587
[TBL] [Abstract][Full Text] [Related]
7. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Boven E; Schipper H; Erkelens CA; Hatty SA; Pinedo HM
Br J Cancer; 1993 Jul; 68(1):52-6. PubMed ID: 8318420
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
[TBL] [Abstract][Full Text] [Related]
9. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
[TBL] [Abstract][Full Text] [Related]
10. [Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
Lehoczky O; Pulay T
Orv Hetil; 2006 Jul; 147(30):1405-8. PubMed ID: 16977778
[TBL] [Abstract][Full Text] [Related]
11. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
13. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
[TBL] [Abstract][Full Text] [Related]
14. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice.
Okino H; Maeyama R; Manabe T; Matsuda T; Tanaka M
Clin Cancer Res; 2003 Nov; 9(15):5786-93. PubMed ID: 14654564
[TBL] [Abstract][Full Text] [Related]
15. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
17. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
19. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
[TBL] [Abstract][Full Text] [Related]
20. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
